ALK and non-small cell lung carcinoma: The primary mode of action of ceritinib in ALK-positive NSCLC patients involves the inhibition of the driver mutation, characterized by the fusion of the 3′ segment of the ALK kinase region with the 5′ portion of another gene, resulting in a constitutively active kinase that triggers downstream signaling pathways [19].